Orthocell Lands First Canada Sales in US$75M Nerve Repair Market Across 6 Countries
Orthocell completes first Remplir sales in Canada’s US$75 million nerve repair market
Regenerative medicine company Orthocell Limited (ASX: OCC) has completed its first commercial sales of Remplir in Canada, marking revenue generation in a sixth market for the flagship nerve repair device. The milestone follows Health Canada approval and distributor appointments in 2H CY25, with the Canadian nerve repair market estimated at approximately US$75 million. Orthocell’s distributors currently provide majority national coverage across Canada, positioning the company to support surgeon and hospital adoption nationwide.
Remplir is now generating revenue in six markets: Australia, New Zealand, the United States, Singapore, Hong Kong, and Canada. The Canadian sales demonstrate the effectiveness of Orthocell’s distributor-led commercialisation model, which enables efficient and capital-light market entry through established relationships with surgeons and hospitals whilst preserving internal resources for larger market opportunities.
KOL-led launch activities drive early adoption
Orthocell worked alongside its distributors on initial launch activities, including a KOL-led product roadshow across Canada from Vancouver to Toronto. The programme featured Australian orthopaedic surgeon Dr Stuart Kirkham, who presented his clinical experience with Remplir to plastic and orthopaedic peripheral nerve surgeons. This approach supported product education and early engagement, contributing to the first commercial sales in the territory.
Key opinion leader endorsement accelerates surgeon confidence in new markets by providing clinical validation from established practitioners. The KOL-led model reduces adoption friction by demonstrating real-world application and outcomes to target physicians evaluating the technology.
When big ASX news breaks, our subscribers know first
What is Remplir and why does peripheral nerve repair matter?
Remplir is a collagen-based nerve repair device used in reconstructive surgery to facilitate peripheral nerve regeneration. Peripheral nerve injuries occur from trauma, surgical complications, or disease, and can result in loss of sensation, motor function, or chronic pain.
Traditional nerve repair methods include direct sutures or nerve grafts harvested from other parts of the patient’s body. These approaches carry limitations, including donor site morbidity and surgical complexity. Collagen-based devices like Remplir provide a scaffold that supports nerve regeneration without requiring tissue harvesting, offering a standardised repair option across varying injury types.
Understanding the clinical role of nerve repair devices helps investors appreciate the addressable market and competitive positioning. Peripheral nerve injuries represent a recurring healthcare need across trauma, oncology, and reconstructive surgery settings, creating sustained demand for approved repair technologies.
Distributor-led model enables capital-light global expansion
Orthocell operates a two-tier commercialisation strategy: distributor-led for non-U.S. markets and company-led for the United States. This approach allows efficient market entry through established distributor relationships with surgeons and hospitals, whilst preserving internal resources for the larger U.S. market opportunity valued at approximately US$1.6 billion.
The company’s U.S.-based marketing and medical education teams support both U.S. and Canadian distributor activities, providing coordinated clinical engagement, training, and operational efficiencies across North America. Orthocell plans expansion into the European and UK markets following expected approval in 2H CY26.
| Market | Regulatory Status | Revenue Status | Estimated Market Size |
|---|---|---|---|
| United States | Approved | Generating revenue | ~US$1.6 billion |
| Canada | Approved | Generating revenue | ~US$75 million |
| EU/UK | Expected 2H CY26 | Pre-launch | ~US$750 million |
| Australia | Approved | Generating revenue | Not disclosed |
| Singapore | Approved | Generating revenue | Not disclosed |
| Hong Kong | Approved | Generating revenue | Not disclosed |
The distributor-led strategy reduces capital requirements for international expansion whilst allowing Orthocell to focus internal sales and marketing resources on the U.S. market, where hospital network approvals continue to expand.
U.S. hospital network continues to expand
Recent U.S. approvals provide Remplir access to a growing network of approximately 336 hospitals, comprising approximately 221 U.S. military medical centres and approximately 115 general hospitals. The network continues to expand, with military medical centres representing a key healthcare segment for Remplir utilisation.
Military healthcare represents high-volume, recurring demand with standardised procurement processes. U.S. Department of Defense hospital networks serve active duty personnel, veterans, and military families, creating a defined patient population with consistent nerve repair requirements across trauma and reconstructive surgery applications.
The next major ASX story will hit our subscribers first
Strong balance sheet supports continued commercial rollout
Orthocell reported a cash position exceeding A$48 million as at 31 March 2026, with no debt. The cash position comprises $7.8 million in cash and cash equivalents plus $40.2 million in term deposits with maturities ranging from three to 12 months. This funding supports continued commercial expansion across current and future markets, including EU/UK market entry following expected approval in 2H CY26.
Paul Anderson, Managing Director
“We are delighted to announce the first commercial sales of Remplir in Canada, a key milestone following Health Canada approval and the roll out of our distributor-led model, which provides coverage across the majority of this ~US$75 million market. This milestone represents an important early step in our Canadian commercialisation strategy and reinforces the strength of our execution. We expect increasing surgeon engagement to support continued adoption and further revenue growth.”
A debt-free balance sheet with substantial cash runway provides flexibility for multi-market execution without near-term dilution risk. The capital position allows Orthocell to fund distributor support activities, U.S. hospital network expansion, and EU/UK regulatory processes whilst maintaining operating reserves for commercial scale-up as adoption increases across approved markets.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to start receiving real-time alerts the moment market-moving announcements break across ASX-listed healthcare and biotech companies.